Generic Pharmaceuticals Pricing

Generic Pharmaceuticals Pricing Antitrust Litigation is among the largest antitrust MDLs ever consolidated, addressing allegations that numerous generic drug manufacturers coordinated pricing across dozens of separate generic drug products, harming direct and indirect purchasers — wholesalers, pharmacies, health plans, and other payors — across the pharmaceutical supply chain. Centralized in the Eastern District of Pennsylvania in 2016, the docket carries 70 pending actions after roughly a decade of litigation, reflecting both the original scale of the alleged multi-drug conspiracy and a claim population that, like the related Automotive Parts matter, is organized around dozens of distinct drug-specific conspiracy tracks rather than a single unified theory.

For a funder, that drug-by-drug structure is the central underwriting reality: a claim tied to one generic drug's pricing conspiracy can be at a very different procedural and evidentiary stage than a claim tied to another, even within the same MDL caption. Diligence has to identify which specific drug conspiracy track a given claim belongs to and how far that track's own settlement or litigation history has progressed, rather than treating the docket as a single homogeneous claim pool.

For a wholesaler, pharmacy chain, or payor holding a portfolio of purchaser claims spanning multiple drug tracks within this docket, inventory finance under Criterica Capital's commercial litigation finance line can work well once each track's posture is mapped, since claim value in more developed drug tracks correlates reasonably predictably with documented purchase volume. This is a commercial purchaser antitrust matter with no medical-lien dimension. A structure and litigation brief distinguishing the docket's various drug-specific tracks is also available.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.